Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Lawmakers Request 4-Valent HPV Vaccination Program for Males to Minister
A parliamentary group under the ruling Liberal Democratic Party (LDP) on November 29 submitted a request to Health Minister Keizo Takemi demanding the coverage of HPV shots for male subjects under the national immunization program (NIP). The league of lawmakers,…
To read the full story
Related Article
- Local Legislators Urge Routine HPV Shots for Males as LDP Group Renews Push
November 25, 2025
- Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
- LDP Lawmakers Seek Early Male NIP Coverage for HPV Jabs
June 18, 2025
- LDP Group Renews Call for Gender-Neutral HPV Vaccination
July 9, 2024
- No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
May 23, 2024
- Lawmakers Demand NIP Coverage for Male Use of 4-Valent HPV Vaccine
October 26, 2023
REGULATORY
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…